Myopia Treatment Devices Market is expected to Grow at a CAGR of 7.57% During the Study Period (2021-30), estimates DelveInsight
"Myopia Treatment Devices Market"
Myopia Treatment Devices companies such as CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others.
(Albany, USA) According to the latest report published by DelveInsight 'Myopia Treatment Devices Market Insight,' the global Myopia Treatment Devices Market is anticipated to witness stellar growth owing to the rising government initiatives to raise awareness among the population regarding myopia treatment, increase in myopia affected cases across the globe, rise in product launches of various advanced myopia management devices. This report will provide an in-depth understanding of the Myopia Treatment Devices market which will further benefit the competitors or stakeholders operating in the Myopia Treatment Devices market.
The Myopia Treatment Devices market is anticipated to boost as the demand for these devices is increasing at a considerable rate owing to the rising prevalence of myopia, worldwide. Additionally, an increase in the adoption rate of Myopia Treatment Devices is further expected to bolster the global market for Myopia Treatment Devices during the forecast period (2024-2030).
Key Takeaways from the Myopia Treatment Devices Market Report
As per DelveInsight estimates, APAC is anticipated to dominate the global Myopia Treatment Devices market during the forecast period.
The leading Myopia Treatment Devices companies such as CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others are currently working in the Myopia Treatment Devices market.
In January 2024, Eyenovia, Inc., a commercial-stage, ophthalmic company, announced that it has re-acquired the rights to MicroPine in the U.S. and Canada. MicroPine, an investigational eight microliter ophthalmic spray of atropine delivered by Eyenovia's proprietary Optejet device, is being evaluated as a potential treatment for pediatric progressive myopia which is characterized by elongation of the sclera/retina.
In October 2023, NIDEK CO LTD launched the NP-1/NP-1C Preloaded IOL Injection System. The NP-1/NP-1C is a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. This newly developed injector is designed for smooth, controlled delivery. The NP-1/NP-1C allows quick and easy operation using a simple two-step process involving, filling the viscoelastic material and pressing the plunger.
On May 25, 2021, CooperVision DreamLite® Ortho-K Lenses gained European approval for slowing the progression of myopia.
On May 12, 2021, Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, launched the latest breakthrough in overnight orthokeratology lens, Euclid MAX in the US.
On April 07, 2021, Menicon entered into a global collaboration with Johnson & Johnson Vision to bring forward therapeutic contact lens-related products and services to manage the progression of myopia in children.
Thus, owing to such developments in the market, there will be rapid growth observed in the Myopia Treatment Devices market during the forecast period.
To read more about the latest highlights related to Myopia Treatment Devices, get a snapshot of the key highlights entailed in the Myopia Treatment Devices Market Report
Myopia Treatment Devices
Myopia, or near-sightedness is a refractive vision disorder that causes blurred sight at a distance. It occurs when the length of the eye (known as axial length) is too great; myopia progresses as axial length increases with age. The devices such as eyeglasses, contact lenses, and Ortho-K lenses, among others which are used to slow down the progression of myopia are termed myopia treatment devices.
Children who are at high risk of progressive myopia (due to a family history of the condition, early age of onset, and lengthy durations of close work) may benefit from treatment options that have been found to slow the advancement of myopia. These treatments for myopia include bifocal spectacle or contact lens prescription, orthokeratology, eye drops, or a combination of these. Myopia control may assist protect eye health since those with extreme myopia are more likely to develop cataracts, glaucoma, and myopic macular degeneration.
Myopia Treatment Devices Market Insights
Geographically, the global Myopia Treatment Devices market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. APAC is projected to witness the fastest growth during the study period. This is owing to the rising prevalence of the targeted population. Moreover, rising government initiatives to raise awareness regarding the proper management of myopia among the population in the region is also a potential factor for Myopia Treatment Devices market growth.
Furthermore, the presence of regional companies such as Menicon Co., Ltd., Kubota Pharmaceutical Holdings Co., Ltd., among others, and their increased focus on developing novel Myopia treatment options will also contribute to the fastest Myopia Treatment Devices market growth in the region. For instance, Kubota Pharmaceutical Holdings Co., Ltd. with its subsidiary Kubota Vision is planning to use the Kubota Glass technology which leverages nanotechnology in an electronic glasses-based device to reduce the progression of myopia by actively stimulating the retina for shorter periods while maintaining high-quality central vision and not affecting daily activities to develop smart contact lenses for the reduction of myopia progression.
To know more about why APAC is leading the market growth in the Small Myopia Treatment Devices market, get a snapshot of the report Myopia Treatment Devices Market
Myopia Treatment Devices Market Dynamics
The Myopia Treatment Devices market is gaining pace at present owing to the growing myopia cases across the globe. Furthermore, approval of various myopia treatment devices in various countries across the globe to slow down the progression of the disease is also projected to augment the Myopia Treatment Devices market in the upcoming years. For instance, on June 03, 2020, SightGlass Vision achieved CE Mark allowing European Marketing Authorization for novel eyeglasses that slow myopia progression in children. The spectacles developed by the company comprise advanced diffusion optics technology spectacle lenses. Hence, the above-mentioned factors are expected to increase the Myopia Treatment Devices market in the future.
However, limitations associated with the refractive surgery procedures and stringent regulatory approval process for the myopia treatment devices are likely to impede the growth of the Myopia Treatment Devices market.
Moreover, the unprecedented COVID-19 impact had sluggish the Myopia Treatment Devices market growth. This is due to the implementation of stringent lockdowns across the nation, and the reduction in clinic visits due to reluctance among patients during the pandemic, among others. However, a sudden shift toward digital or e-learning approaches from classroom-based learning has subsequently increased myopia and its progression among the students. For instance, as per the report published by UNESCO in the year 2020, approximately 1.37 billion students from more than 130 countries globally were affected by the pandemic as the schools and universities adopted digital learning during the pandemic to curb the infection.
Thus, it is expected to increase the risk of myopia among the children which will increase the demand for the myopia treatment devices during the post-pandemic situation, thus the Myopia Treatment Devices market will gain normalcy.
Scope of the Myopia Treatment Devices Market Report
Coverage: Global
Study Period: 2021-2030
Market Segmentation By Treatment - Corrective Lenses, Laser Eye Surgery, Lens Implant Surgery
Market Segmentation By Product Type - Eyeglasses, Contact Lenses, Ortho-K Lenses, Phakic Intraocular Lenses, Excimer Laser Refractive Surgery Devices
Market Segmentation By End-User - Hospitals, Specialty Clinics, and Others
Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World
Key Myopia Treatment Devices Companies - CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, among others
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
DelveInsight Analysis: The Myopia Treatment Devices market size is expected to grow at a CAGR of 7.57% during the study period (2021-30).
Table of Contents
1. Report Introduction
2. Executive summary
3. Regulatory and Patent Analysis
4. Key Factors Analysis
5. Porter's Five Forces Analysis
6. COVID-19 Impact Analysis on Myopia Treatment Devices Market
7. Myopia Treatment Devices Market Layout
8. Global Company Share Analysis – Key 3-5 Companies
9. Myopia Treatment Devices Market Company and Product Profiles
10. Project Approach
11. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
Jets owner Woody Johnson buys 43% stake in English soccer club Crystal Palace
LONDON (AP) — New York Jets owner Woody Johnson is finally set to get his hands on an English soccer team. Premier League side Crystal Palace announced on Monday that Johnson has signed 'a legally binding contract' to buy the shares of fellow American John Textor, who has a 43% stake in the London club. Reports have placed the price between $220 million and $260 million. 'Whilst the completion is pending approval from the Premier League and Women's Super League, we do not envisage any issues and look forward to welcoming Woody as a partner and director of the club,' Palace said in a statement. 'We would like to go on record to thank John Textor for his contribution over the past four years and wish him every success for the future.' Johnson submitted a bid to buy Chelsea in 2022 but was unsuccessful. The sale of Textor's shares boosts Palace's hopes of playing in the Europa League next season, having qualified thanks to its FA Cup final victory over Manchester City last month. Textor is also a shareholder in French side Lyon, which is set to enter the same competition, and under UEFA multi-club ownership rules, it looked as if Palace could miss out. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. ___ AP soccer:
Cision Canada
2 days ago
- Cision Canada
Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM
World's leading* contact lens brand ACUVUE brings pioneering innovation for astigmatic patients with presbyopia, providing visual clarity and comfort 1 Launch reinforces Johnson & Johnson's position as world leader in contact lenses* – pushing boundaries in optical and material science JACKSONVILLE, Fla., June 23, 2025 /CNW/ -- Today, Johnson & Johnson, † a global leader in eye health, announced the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and only daily disposable contact lens for people with both astigmatism and presbyopia. 2 This pioneering contact lens provides patients crisp, clear, stable vision at all distances and in all lighting conditions, along with comfort that lasts all day. 1 The lens is now available in the U.S. and Canada, and the launch of ACUVUE OASYS MAX 1-Day for ASTIGMATISM is expected later this summer. Experience the full interactive Multichannel News Release here: "Building on our legacy of firsts, we are thrilled to launch ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM," said Peter Menziuso, Company Group Chairman, Vision at Johnson & Johnson. ‡"ACUVUE is the world's leading contact lens brand* and with these new products, we now have the first and only complete family of daily-disposable contact lenses. # 2 Clear sight empowers people to live their best lives, and we believe everyone should have the opportunity to achieve it. That's why we focus our innovation on areas with the greatest unmet needs for patients. Today, we are working to fulfill that promise, providing millions of patients with a differentiated ACUVUE experience." "Finally, patients with both presbyopia and astigmatism can enjoy the freedom and comfort of a daily disposable lens without compromising the quality of their vision," said Dr. Mark Wells, "This new lens was designed to help patients who struggle with multiple vision correction issues, allowing them to experience the comfort and clarity of MAX." 1 Based on extensive studies, 95% of people wearing ACUVUE OASYS MAX 1-DAY MULTIFOCAL for ASTIGMATISM contact lenses reported their vision was clear during their daily activities, § 1 while 87% saw clearly while driving at night. § 1 Additionally, 92% of wearers said their eyes felt comfortable throughout the entire day. ¶ 1 Astigmatism affects about 50% of the population, 3 making it one of the most common vision conditions. It is characterized by imperfections in the curvature of the eye, leading to distorted or blurred vision. Presbyopia, commonly beginning in the early to mid-40s, is the gradual loss of near vision. Traditionally, there has been a gap for people with astigmatism when they begin to experience presbyopia. They've had to make compromises by either switching from daily contact lenses to reusables, or layering reading glasses over their contact lenses. The ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM contact lens is built with the combination of four proprietary technologies 4 which enable its comfort and visual results: BLINK STABILIZED Design helps the lens stay put, so vision is not distorted or blurry when you blink or move your head. 1,4 PUPIL OPTIMIZED Design helps meet presbyopic vision needs, even as you age and your vision continues to change. 5 TearStable Technology helps keep the lens hydrated, facilitating end of day comfort. †† 1,6,7,8 Finally, the OptiBlue Light Filter provides 60% blue-violet light filtering, the highest in the industry.** ‡‡ 7,8 Later this summer, the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lens will launch in both the U.S. and Canada, making the ACUVUE OASYS MAX 1-Day Family of lenses the first and only complete daily disposable family of contact lenses on the market. # 2 Both ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM and ACUVUE OASYS MAX 1-Day for ASTIGMATISM are planned to be introduced in additional markets outside North America during 2025 and beyond. To learn more about ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM or to search for an eye care provider, visit † About Vision at Johnson & Johnson Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at Follow us at @JNJMedTech and on LinkedIn. Johnson & Johnson Vision Care, Inc., a Johnson & Johnson Company. * Source Euromonitor International Limited; Eyewear 2025 edition; value sales at rsp, all retail channels, 2023 data; "ACUVUE ® family of brands" represents aggregated sales of the following brands: 1-day ACUVUE ®, ACUVUE ® OASYS, ACUVUE ® VITA ®, and ACUVUE ® 2. ‡ Peter Menziuso is an employee of Johnson & Johnson # Full/complete family consists of sphere, multifocal, toric, and multifocal toric contact lenses § Model-adjusted percent estimate ¶ T3B descriptive summaries: n=171 **Filtering of HEV light by contact lenses has not been demonstrated to confer any health benefit to the user, including but not limited to retinal protection, protection from cataract progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted for more information. †† Versus ACUVUE ® OASYS 1-Day, Dailies Total1 ®, My Day ®, Infuse™ and Precision 1 ®. ‡‡ Versus publicly available information for standard daily use contact lenses as of December 2023. © Johnson & Johnson and its affiliates 2025 2025PP10152 1 JJV Data on file, 2024: Subjective Standalone Claims for ACUVUE® OASYS MAX 1-Day MULTIFOCAL Contact Lenses for ASTIGMATISM 2 JJV Data on File 2025, World's First and Only Daily Disposable Multifocal Toric Contact Lens 3 Young G, Sulley A & Hunt C. Prevalence of Astigmatism in Relation to Soft Contact Lens Fitting; Eye & CL, 2011: 37: 20-25 4 JJV Data on File: Technical Description of ACUVUE ® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM 5 JJV Data on File 2020. ACUVUE OASYS MULTIFOCAL Fit and Performance Claims 6 JJV Data on File 2022. Effect on Tear Film and Evaluation of Visual Artifacts with ACUVUE ® OASYS MAX 1-Day Family. 7 JJV Data on File 2022. JJV Data on File 2022 TearStable™ Technology Definition. 8 JJV Data on File 2022. Material Properties: 1-DAY ACUVUE ® MOIST, 1-DAY ACUVUE ® TruEye ®, ACUVUE ® OASYS 1-Day with HydraLuxe ® Technology and ACUVUE ® OASYS MAX 1-Day with TearStable™ Technology Brand Contact Lenses and other daily disposable contact lens brands. Important information for contact lens wearers: ACUVUE Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and the lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional, call 1-800-843-2020, or download the Patient Instruction Guides. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM and ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments Kristyna Muñoz [email protected] Investor Contact: Sandra Easton [email protected]
Cision Canada
17-06-2025
- Cision Canada
Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting*†‡1,6
The new full visual range* 1 IOL enables 93% of patients to become free from glasses at all distances.** 2 *** With best-in-class image contrast and low-light performance, #~3,4,5 TECNIS Odyssey IOL expands the Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs. TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes. ∫ 7,15 This content is intended for Healthcare Professionals only, not for the general public. JACKSONVILLE, Fla., June 17, 2025 /CNW/ -- Johnson & Johnson, § a global leader in eye health, announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC - IOL) with the roll-out of TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The new full visual range *1 IOL offers high-quality and continuous vision with unmatched range. $6,16 This will allow patients to see clearly from far to near and in between, minimizing their need for glasses. ‡+2,6,7 Built on the industry-leading TECNIS platform, combining advanced optics and proprietary materials, TECNIS Odyssey IOL offers consistently clear, high-contrast vision. "TECNIS Odyssey IOL is the fastest growing PC-IOL in the United States, ^ and we are excited to be making it available to more patients around the world. It addresses a significant unmet need for cataract patients seeking greater spectacle independence. + Now – together with TECNIS PureSee – TECNIS Odyssey IOL elevates the strength and depth of our global IOL portfolio, meeting the diverse needs of today's aging population," said Peter Menziuso, Company Group Chairman, Vision, Johnson & Johnson. Currently, an estimated 94 million people aged 50 years and over have moderate-to-severe distance vision impairment or blindness that could be corrected through lens replacement surgery. 8 These figures are projected to increase, since presbyopia and cataract development are part of the aging process. Presbyopia is a progressive eye condition that makes it difficult to focus on close objects and usually becomes noticeable around 40 years of age. 9 Full visual range IOLs provide the opportunity to correct presbyopia at the time of lens replacement surgery. "From my early experience, what sets the TECNIS Odyssey IOL apart, is its ability to deliver consistent visual outcomes across a wide range of patients, due to its advanced design with higher tolerance to residual refractive error," ∫ 7,11 said Professor Beatrice Cochener-Lamard, Head of the Ophthalmology Department at Brest University Hospital in France. ^^^ TECNIS Odyssey IOL is the latest innovation for those seeking greater visual freedom – offering: Precise vision: TECNIS Odyssey IOL provides crisp and clear vision, allowing patients to see with clarity at every distance 6 - whether they are reading, driving or engaging in daily activities. 94% of patients were satisfied with their overall vision without glasses. &****12 At every distance: Its unique, freeform diffractive surface was designed to eliminate the gaps between near, intermediate and far distances, and offer continuous, uninterrupted vision at all distances. †‡6 96% of patients were satisfied with reading a smartphone or tablet, &****13 and 97% were satisfied with distance vision. &****12 In any lighting: Engineered to minimize night vision disturbances – fewer halos and glare #14 – TECNIS Odyssey IOL provides better image quality than PanOptix day and night, ##3,4,5 for a more comfortable night-time experience. 92% of patients were satisfied with their ability to see steps and read street signs at night. &****13 With a variety of options for different visual needs and lifestyles, the TECNIS platform empowers more patients to find the right solution. The Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs available in Europe, the Middle East, Canada, and Japan now includes both TECNIS Odyssey IOL and TECNIS PureSee IOL. TECNIS Odyssey IOL, the full range of vision IOL, is also available in the US, Puerto Rico, and Japan. TECNIS PureSee IOL, the purely refractive, extended depth of focus IOL, is also available across APAC and Latin America. TECNIS PureSee has not received PMA Approval in the U.S. For more patient information and tools please visit Visit us at and and follow Johnson & Johnson | Vision on LinkedIn. About Vision at Johnson & Johnson Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at Follow us at @JNJMedTech and on LinkedIn. Johnson & Johnson Surgical Vision, Inc. is part of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of TECNIS Odyssey™ intraocular lens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Footnotes *According to ISO 11979-7:2024, based on the clinical study of the parent IOL **(n=82) 1 month results. Q: "Was the patient wearing any spectacles or contact lenses since the surgery?" Six subjects 6/82 (5 subjects for near, 1 subject for both distance and near); ***Based on 1-month postoperative data from a multicenter, retrospective, real-world clinical study in the U.S. evaluating visual and patient-reported outcomes from subjects bilaterally implanted with TECNIS Odyssey™ IOL (n=96). ****Based on 3-month postoperative data from a multicenter, observational clinical study in the U.S. evaluating visual and patient-reported outcomes from subjects bilaterally implanted with TECNIS Odyssey™ IOL (n=33). ¶based on pre-clinical bench testing. The third-party trademarks used herein are the trademarks of their respective owners. ∫compared to TECNIS Synergy™ and TECNIS™ Multifocal IOLs based on pre-clinical bench testing #compared to PanOptix ® based on pre-clinical bench testing ##compared to leading competitor full visual range IOLs based on pre-clinical bench testing (white light MTF at 50 c/mm measured for 3mm & 5mm pupil in the ACE model) §Johnson & Johnson represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both. †continuous 20/25 or better ‡based on pre-clinical bench testing ^based on Market Scope's estimated procedure for 2024 vs 2023 ^^^Professor Beatrice Cochener-Lamard is a paid consultant of Johnson & Johnson MedTech ~Compared to TECNIS SYNERGY™ based on bench testing +Individual results will vary. Some TECNIS Odyssey™ IOL patients may require spectacles post-surgery. -Results may vary. Consult your doctor to determine the lens options that are right for you. $Compared to PanOptix ® based on bench testing and head-to-head clinical studies of parent lens &Values rounded to the nearest 1% Indication and safety information in regions where these products are available for use is included below. Please note indications may differ based on region. Full safety information is available hyperlinked below. IN THE UNITED KINGDOM The promoted product is a medical device. For healthcare professionals only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question. IN CANADA INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR TECNIS ODYSSEY™ IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DRN00V AND TECNIS ODYSSEY™ TORIC II IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELS DRT100, DRT150, DRT225, DRT300, DRT375, IN CANADA: Rx Only INDICATIONS FOR USE: The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL which is indicated for primary implantation for the visual correction of aphakia in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs which are indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing vision far through near and reduced spectacle dependence across a range of distances. The lens is intended to be placed in the capsular bag. Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of the possibility of visual effects (such as halo or glare), in nighttime or poor visibility conditions. Patients may perceive these visual effects as an annoyance or hindrance, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of potential spectacle independence. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. Care should be taken to achieve centration of the toric IOL. Safety and effectiveness in patients 21 years or younger have not been established in clinical studies. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information. INDICATIONS FOR USE The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ IOL which is indicated for primary implantation for the visual correction of aphakia, in adult patients with less than 1 diopter of preexisting corneal astigmatism, in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, and decreased spectacle dependence. The lens is intended for capsular bag placement only. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS PureSee™ Toric II IOL which is indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, a reduction of residual refractive cylinder, and decreased spectacle dependence. The lens is intended for capsular bag placement only. WARNING Physicians should weigh the potential risk/benefit ratio of IOL implantation in patients with any of the conditions described in the Directions for Use. These conditions are not specific to the design of the IOL and are attributed to cataract surgery and/or IOL implantation in general. The IOL should be placed entirely in the capsular bag. Do not place the IOL in the ciliary sulcus. Patients should be informed of the possibility of visual disturbances. The lens may cause a reduction in contrast sensitivity under certain conditions, compared to an aspheric monofocal IOL; fully inform the patient of this risk before implanting the lens. Special consideration should be made for patients with macular disease, amblyopia, corneal irregularities, or other ocular disease. Inform patients to exercise special caution when driving at night or in poor visibility conditions. Rotation of the TECNIS PureSee™ Toric II IOL away from their intended axis can reduce their astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, IOL repositioning should occur as early as possible prior to lens encapsulation. Do not attempt to disassemble, modify, or alter the delivery system, or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not use if the cartridge tip is cracked or split. Do not implant the IOL if the rod tip does not advance the IOL or if it is jammed in the delivery system. Do not advance the IOL from the Holding Position (located at the half turn rotation position for the initial advancement of the IOL into the cartridge) prior to fully hydrating the system and ready for implantation. A minimum of 1 minute at the Holding Position is required to fully hydrate the system to prevent sticking and a potential scratch or crack to the IOL. Interruptions during delivery may result in the IOL being scratched or cracked or stuck in the cartridge. Discard the device if the IOL has been advanced past the Holding Position but not delivered within 60 seconds. The IOL and delivery system should be discarded if the IOL has been folded within the cartridge for more than 10 minutes. Not doing so may result in the IOL being stuck in the cartridge. PRECAUTIONS Autorefractors may not provide optimal postoperative refraction of patients with the IOL. Manual refraction with maximum plus technique is strongly recommended. Recent contact lens usage may affect the patient's refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Target emmetropia for optimum visual performance. For the TECNIS PureSee™ Toric II IOL, variability in any preoperative surgical parameters (e.g., keratometric cylinder, incision location, estimated surgically induced astigmatism, or biometry) can influence patient outcomes. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case, to avoid lens rotation. This is a single use device, do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F). Do not autoclave the delivery system. Do not advance the lens unless ready for lens implantation. The contents are sterile unless the package is opened or damaged. The recommended temperature for implanting the lens is at least 17°C (63°F). The use of balanced salt solution or viscoelastics is required when using the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. ADVERSE EVENTS Potential adverse events during or following cataract surgery with implantation of the IOL may include but are not limited to: Endophthalmitis/intraocular infection, IOL dislocation, persistent cystoid macular edema, persistent corneal stromal edema, persistent raised intraocular pressure (IOP) requiring treatment, secondary surgical intervention (including implant repositioning, removal, AC tap, or other surgical procedure). Adverse events can lead to permanent visual impairment and may require secondary surgical intervention, including intraocular lens exchange or explanation. ATTENTION Reference the Directions for Use for a complete listing of Indications and Important Safety Information. IN THE UNITED STATES Rx Only INDICATIONS: The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ IOL, which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS SIMPLICITY™ Delivery System is used to fold and assist in inserting the TECNIS Odyssey™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Odyssey™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only. WARNINGS: Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Odyssey™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Odyssey™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Odyssey™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Odyssey™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Odyssey™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Odyssey™ IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism. ------------------------------------------------- 1 Data on File. 2024DOF4002 (prospective, multicenter, randomized, three-way-masked clinical study comparing subjects bilaterally implanted with TECNIS Synergy IOL (n=132) vs TECNIS 1-Piece Monofocal IOL (n=131) at 6-months post-op) 2 Data on File. DOF2023CT4051. 3 Data on File. 2024DOF4033 4 Data on File. DOF2019OTH4002 5 Data on File. DOF2023CT4007 6 Data on File. DOF2023CT4023 7 Data on File. 2024DOF4003 8 World report on vision. Geneva: World Health Organization, 2019. Available at: Last accessed: May 2025. 9 What Is Presbyopia – American Academy of Ophthalmology. Access from: 2024REF5075. 11 Data on File. 2024DOF4017 12 Data on File. 2024DOF4027. 13 Data on File. 2024DOF4029. 14 Data on File. 2024DOF4005 15 DOF2023CT4052 16 DOF2020CT4014 Media contact (EMEA): Sarah Smith [email protected] Media contact (NA): Maggie Lorenz [email protected] Investor contact: Sandra Easton [email protected]
